共 8 条
- [4] Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association LIPIDS IN HEALTH AND DISEASE, 2016, 15
- [6] Scientific Opinion on the substantiation of health claims related to the raw fruit of Emblica officinalis Gaertn. and maintenance of normal blood LDL-cholesterol concentrations (ID 4041) and protection of DNA, proteins and lipids from oxidative damage (ID 4042) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 EFSA JOURNAL, 2011, 9 (06)
- [7] Scientific Opinion on the substantiation of health claims related to Camellia sinensis (L.) Kuntze (tea), including catechins in green tea, and improvement of endothelium-dependent vasodilation (ID 1106, 1310), maintenance of normal blood pressure (ID 1310, 2657), maintenance of normal blood glucose concentrations (ID 1108), maintenance of normal blood LDL-cholesterol concentrations (ID 2640), protection of the skin from UV-induced (including photo-oxidative) damage (ID 1110, 1119), protection of DNA from oxidative damage (ID 1120, 1121), protection of lipids from oxidative damage (ID 1275), contribution to normal cognitive function (ID 1117, 2812), "cardiovascular system" (ID 2814), "invigoration of the body" (ID 1274, 3280), decreasing potentially pathogenic gastrointestinal microorganisms (ID 1118), "immune health" (ID 1273) and "mouth" (ID 2813) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) EFSA JOURNAL, 2011, 9 (04)
- [8] Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), "cardiovascular health" (ID 3587), treatment of prostate cancer (ID 3588) and "upper respiratory tract" (ID 3589) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 EFSA JOURNAL, 2011, 9 (07)